Lieke Maas

Lieke Maas

Auto-generated profile, based on publicly available information

Lieke Maas

Maastricht University

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2025 in Journal of Medical Economics
Verified
Journal Article
Open access
LML. Maas
L. Maas
CCC. Contreras-Meca
C. Contreras-Meca
SGSamuele Ghezzo
Samuele Ghezzo
FBF. Belmans
F. Belmans
ACAndrea Corsi
Andrea Corsi
JRJavier del Riego
Javier del Riego
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third most common cause of cancer-related death. Cirrhosis is a major contributing factor, accounting for over 90% of HCC cases. With the high mortality rate of HCC, earlier detection of HCC is critical. When added to magnetic resonance imaging (MRI), artificial intelligence (AI) has been shown to improve HCC detection. Nonetheless, to date no cost-effectiveness analyses have been conducted on an AI tool to enhance earlier HCC detection. This study reports on the cost-effectiveness of detection of liver lesions with AI improved MRI in the surveillance for HCC in patients with a cirrhotic liver compared to usual care (UC). The model structure included a decision tree followed by a state-transition Markov model from an Italian healthcare perspective. Lifetime costs and quality-adjusted life years (QALY) were simulated in cirrhotic patients at risk of HCC. One-way sensitivity analyses and two-way sensitivity analyses were performed. Results were presented as incremental cost-effectiveness ratios (ICER). For patients receiving UC, the average lifetime costs per 1,000 patients were €16,604,800 compared to €16,610,250 for patients receiving the AI approach. With a QALY gained of 0.55 and incremental costs of €5,000 for every 1,000 patients, the ICER was €9,888 per QALY gained, indicating cost-effectiveness with the willingness-to-pay threshold of €33,000/QALY gained. Main drivers of cost-effectiveness included the cost and performance (sensitivity and specificity) of the AI tool. This study suggests that an AI-based approach to earlier detect HCC in cirrhotic patients can be cost-effective. By incorporating cost-effective AI-based approaches in clinical practice, patient outcomes and healthcare efficiency are improved.

21 September 2023 in Osteoporosis International
Verified
Journal Article
Open access
PDF file
LMLieke Maas
Lieke Maas
NRNele Raskin
Nele Raskin
MOMarloes van Onna
Marloes van Onna
DCDennis Cornelissen
Dennis Cornelissen
SBSandrine Bours
Sandrine Bours
ABAnnelies Boonen
Annelies Boonen
Summary This study describes the development of a decision aid (DA), aimed at supporting patients in their decision whether to start anti-osteoporosis medication. People with recent fractures or osteoporosis and health professionals were supportive of the DA initiative. An experimental study been started to assess (cost-)effectiveness of the DA. Purpose At fracture liaison services (FLS), patients with a recent fracture ánd osteoporosis or a prevalent vertebral fracture are advised to start anti-osteoporosis medication (AOM). This study describes the development of a decision aid (DA) to support patients and healthcare providers (HCPs) in their decision about whether to start AOM. Methods The DA was developed according to International Patient Decision Aid Standards (IPDAS). A systematic procedure was chosen including scope, design, prototype development, and alpha testing. A previously developed DA for women with osteoporosis was used as a basis. Furthermore, input from literature searches, the Dutch guideline on management of osteoporosis, and from people with a fracture or osteoporosis was used. The updated DA was evaluated during alpha testing. Results The DA facilitates the decision of patients whether to initiate AOM treatment and provides information on fractures and osteoporosis, general risk factors that increase the likelihood of a subsequent fracture, the role of lifestyle, personalized risk considerations of a subsequent fracture with and without AOM treatment, and AOM options and their characteristics in an option grid. Alpha testing with 15 patients revealed that patient preferences and needs were adequately presented, and several suggestions for improvement (e.g. adding more specific information, simplifying terminology, improving icon use) were accounted for. Participants from the alpha testing recommended use of the DA during outpatient visits. Conclusion Professionals and persons with osteoporosis were supportive of the proposed DA and its usability. The DA could help in a shared decision-making process between patients and HCPs.

19 November 2023 in Epilepsy & Behavior Reports
Verified
Journal Article
Open access
LML. Maas
L. Maas
JKJ. Kellenaers
J. Kellenaers
GMG. van Mastrigt
G. van Mastrigt
SKS.M.J van Kuijk
S.M.J van Kuijk
MVM.C.G. Vlooswijk
M.C.G. Vlooswijk
KRK. Rijkers
K. Rijkers
• Societal costs decrease over the first year after resective epilepsy surgery. • Quality of life increases after resective epilepsy surgery. • Seizure freedom is reached in 73% of cases one year after resective epilepsy surgery.

30 September 2024 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
LMLieke Maas
Lieke Maas
MHMickaël Hiligsmann
Mickaël Hiligsmann
CWCaroline E. Wyers
Caroline E. Wyers
SBSandrine Bours
Sandrine Bours
TWTrudy van der Weijden
Trudy van der Weijden
ABAnnelies Boonen
Annelies Boonen
Shared decision-making (SDM) aims to improve patients’ experiences with care, treatment adherence, and health outcomes. However, the effectiveness of SDM in patients with a recent fracture who require anti-osteoporosis medication (AOM) is unclear. The objective of this study was to assess the effectiveness of a multicomponent adherence intervention (MCAI) including a patient decision aid (PDA) and motivational interviewing at Fracture Liaison Services (FLS) on multiple outcomes compared with usual care (UC). This pre-post superiority study included patients with a recent fracture attending FLS and with AOM treatment indication. The primary outcome was 1-year AOM persistence measured by pharmacy records. Secondary outcomes included treatment initiation, AOM adherence (measured by medication possession ratio [MPR]), decision quality (SDM process; 0–100, best), and decisional conflict (0–100, highest conflict), subsequent fractures, and mortality. Outcomes were tested in MCAI and UC groups at the first FLS visit and 4 and 12 months afterwards. Multiple imputation and uni- and multivariable analyses were performed. Post hoc analyses assessed the role of health literacy level. In total, 245 patients (MCAI: n = 136, UC: n = 109) were included. AOM persistence was 80.4% in the MCAI and 76.7% in the UC group (p=.626). SDM process scores were significantly better in MCAI (60.4 vs 55.1; p = .003). AOM initiation (97.8% vs 97.5%), MPR (90.9% vs 88.3%, p=.582), and decisional conflict (21.7 vs 23.0; p = .314) did not differ between groups. Results did not change importantly after adjustment. Stratified analyses by health literacy showed a better effect on MPR and SDM in those with adequate health literacy. This study showed no significant effect on AOM persistence; however, it demonstrated a significant positive effect of MCAI on SDM process in FLS attendees. (Netherlands Trial Registry, Trial NL7236 [NTR7435]; version 1.0; 26-11-2020 https://onderzoekmetmensen.nl/nl/trial/22858). When patients participate in the decision-making process (called shared decision-making), we may be able to improve the way they take medication and experience care. We wanted to study how shared decision-making works in people who recently broke a bone and therefore needed anti-osteoporosis medication. We looked at 2 approaches that specialized nurses could use at the clinic. During the first visit, the nurses used a decision aid to discuss different medication options with the patient. During the second visit, nurses used “motivational interviewing” to better understand and support patients with taking their medication in the long term. We compared 109 patients who participated in this study with 126 patients who received normal care without the approaches. We found that the 2 approaches did not change the way people take their medication 1 year after the visits. However, patients who experienced the new approaches felt more involved in all phases of the decision to start and continue medication compared with patients receiving usual care. One year after the visits, people with higher health literacy were more likely to feel like they had been involved in the decision-making process, and more likely to continue to take their medication as prescribed.

9 July 2025 in Expert Review of Pharmacoeconomics & Outcomes Research
Verified
Journal Article
Open access
ERE. Reith
E. Reith
LML. Maas
L. Maas
AJA. Joos
A. Joos
IHI. Heikkinen
I. Heikkinen
MIM. De Iaco
M. De Iaco
MHM. Hiligsmann
M. Hiligsmann
With increasing efforts of streamlining market access of innovative drugs, current acceptance of health technology assessment (HTA) bodies on non-traditional trial designs is still unclear. The aim of this study was to assess the perspective of drug developers on the acceptance of non-traditional trial designs by HTA bodies in Europe. Eleven semi-structured interviews were conducted with experts to gain insights on their perception of non-traditional trial design acceptance by HTA bodies from the Netherlands, Germany, United Kingdom, Sweden, and France. Future perspectives on and recommendations for facilitating the acceptance of non-traditional trials were provided. All experts highlighted the HTA bodies' preference for randomized controlled trials over non-traditional trial designs. The degree of acceptance varied between countries. Experts recommended multistakeholder discussions between drug developers and HTA bodies for early scientific advice and re-evaluation of evidence requirements. The EU-HTA regulation was viewed as both a potential opportunity for harmonization and limiting innovative approach. The results of this study highlighted significant variations in the acceptance of non-traditional trial designs by HTA bodies across Europe. Actions are needed to facilitate a more progressive view on non-traditional clinical trial designs to ensure fast patient access to highly innovative treatments.

3 January 2024 in Therapeutic Innovation & Regulatory Science
Verified
Journal Article
Open access
PDF file
LMLieke Maas
Lieke Maas
AJAngelika Joos
Angelika Joos
MHMickael Hiligsmann
Mickael Hiligsmann
Objectives: This qualitative study aims to analyze current PM regulation and market access requirements and proposes potential solutions to mitigate current challenges. Methods: Twenty-two semi-structured interviews were conducted with experts from pharmaceutical industry, regulatory authorities, national health technology assessment (HTA) bodies, pediatricians, and academia from the Netherlands (NL), Germany (DE), the United Kingdom (UK), and France (FR) to get insight into the pediatric research, the regulatory and reimbursement processes, challenges, and solutions. Themes for further testing were developed on how to facilitate pediatric market access. Atlas.ti 9 was used to analyze the findings. Results: Heterogeneity in requirements for the European Medicines Agency (EMA) and HTA approvals are noted. By example, DE grants direct reimbursement after regulatory approval, the other countries require additional reimbursement which generate delays and challenges in patient access after marketing authorization. Key components in facilitating PM market access include multi-stakeholder collaboration, transparency, patient representatives, informed consent guidance, real-world evidence, and appropriate clinical trial designs. Pricing models based on the economic capabilities of individual countries could further reduce delays and challenges in market access. The additional specific pediatric incentives should be taken as best practice to encourage innovation in pediatric conditions. Conclusion: This study highlights differences in requirements for regulatory and reimbursement approval, along with international differences in pricing and reimbursement procedures for pediatric market access.